

EFFECTIVENESS OF COMBINATION THERAPY WITH FLUTICASONE PROPIONATE AND FORMOTEROLFUMARATE DELIVERED SEPARATELY IN ASTHMA PATIENTS

**S. V. Zaikov, O. H. Bashyrova, I. A. Bolshakova, N. M. Kochetova,
M. D. Liabakh, V. M. Morkotun, L. V. Cherkaska, I. V. Shveikin,
U. I. Shermetynska**

Abstract

The objective of this study is to evaluate the effectiveness and safety of the therapy with combination fluticasone propionate (Flutixon) and formoterol fumarate (Zafiron) delivered separately in patients with asthma (A).

Material and methods. 85 patients were with uncontrolled or partly controlled A were examined. All of them were prescribed combination therapy with fluticasone propionate (Flutixon 124 µg or 250 µg twice daily) and formoterol fumarate (Zafiron 12 µg twice daily) at the first visit. These drugs were used in separate combination through one inhaler. New generation cyclochaler Fantasmio was used as a delivery device for both formulations. The effectiveness and safety of the therapy was evaluated at visits 4, 8 and 12 weeks using Asthma Control Questionnaire (ACQ 6-scores), physical examination and spirometry.

Results. In the majority of patients the control over the disease was achieved in 4-8 weeks according to ACQ score, physical examination and spirometry data. The tolerability of the therapy was satisfactory. No adverse events were registered throughout the study and the follow-up period.

Conclusion. Based on study results the combination of fluticasone propionate and formoterol fumarate, delivered separately using new generation cyclochaler Fantasmio is recommended for management of patients with asthma.

Key words: asthma, fluticasone propionate, formoterol fumarate, new generation cyclochaler Fantasmio.

Ukr. Pulmonol. J. 2015; 1:45–48.

Serhiy V. Zaikov

National medical academy for advanced training named after P. L. Shupik

Professor of phthysiology and pulmonology department

Doctor of medicine, professor

10, M. Amosova str., 03680, Kyiv

Tel.: 380503317773, zaikov1960@gmail.com